Skip to main content
. Author manuscript; available in PMC: 2011 Feb 26.
Published in final edited form as: J Neuroimmunol. 2009 Dec 4;219(1-2):100–104. doi: 10.1016/j.jneuroim.2009.11.013

TABLE 2.

Evidence of “IRIS” in Patients with PML early after initiating HAART (group UPML)

Case no. sex, age,
ethnicity
HAART
initiation
to PML
onset
(days)
HAART regimen means of
diagnosis
clinical
features
localization MRI
evidence of
inflammatory
reactions
CD4
count
(cells/μl)
at PML
onset
HIV viral
load
(copies/ml)
at PML
onset
treatment
w/
cidofovir
outcome
(days of
survival)
1 F, 41, Latino 140 3TC, TDF, lopinavir/ritonavir CSF JCV ⊕, clinical, radiological headache, photophobia, memory loss R middle cerebellar peduncle lesion no enhancement 57 undetectable + unknown
2 M, 36, Caucasian 111 3TC, d4T, efavirenz, nelfinavir CSF JCV ⊕, clinical, radiological headache, photophobia, CN VI & VII palsies bilateral cerebellar hemispheric lesions contrast enhancement 45 undetectable + survived (>400 days) with clinical improvement
3 F, 27, Latino 77 3TC, TDF, lopinavir/ritonavir CSF JCV ⊕, clinical, radiological speech disturbances, CN VII palsy L cerebellum & cerebellar peduncle lesions no enhancement 47 undetectable + survived (>400 days) with clinical improvement
4 F, 52, African-American 77 3TC, AZT, d4T, nelfinavir, indinavir CSF JCV ⊕, clinical ataxia n.a. n.a. 274 undetectable + survived (>400 days) with clinical improvement
5 F, 32, African-American 47 FTC, TDF, atazanavir CSF JCV ⊕, clinical, radiological ataxia, CN VII palsy R middle cerebellar peduncle lesion no enhancement 20 929 survived (>400 days) with clinical improvement
6 M, 35, Caucasian 47 3TC, d4T, nelfinavir CSF JCV ⊕, clinical, radiological vision abnormalities, speech disturbances, CN V, VI &VII palsies multiple patchy enhancing lesions mild contrast enhancement 50 undetectable + survived (>400 days) with clinical improvement
7 M, 51, Latino 110 3TC, AZT, saquinavir CSF JCV ⊕, clinical, radiological visual abnormalities, ataxia, dizziness L frontal, temporal; R frontal, brainstem (including VI nucleus) mild contrast enhancement 26 1800 unknown
8 M, 30, African-American 82 abacavir, d4T, amprenavir CSF JCV ⊕, clinical, radiological gait abnormalities, ataxia, confusion diffuse asymmetric lesions in white matter no enhancement 83 n.a. + unknown
Summary of eight UCSD cases M:F 4:4 median age = 35.5 median = 80 days 2 NRTI + 1 PI regimen CSF JCV ⊕ clinical + radiological ataxia (N = 4) CN palsies (N = 4) photophobia (N =2) speech disturbances (N = 2) visual abnormalities (N = 2) 4 of 8: lesions confined to the cerebellum +/− cerebellar peduncles 3 of 7: contrast enhancement median = 48 range = 20 − 274 6 of 8: undetectable viral load 6 of 8: cidofovir treatment 5 survived; 4 unknown
Summary of thirteen published cases* M:F 10:3 median age = 37 median = 35 days 2 NRTI + 1 PI regimen 9 of 13: CSF JCV ⊕ 3 of 13: clinical or radiological 1 of 13: biopsy 4 of 13: contrast enhancement median = 241 range = 23 – 419 5 of 12: undetectable viral load 9 survived; 8 died